In the fast‑moving world of antibody engineering, few technologies have captured as much attention recently as single‑domain antibodies (sdAbs). Their rise reflects a broader shift in biomedical research: scientists are increasingly prioritizing molecular tools that are smaller, faster, and more adaptable than traditional monoclonal antibodies. As global interest accelerates—from...
English
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)